In The Literature: Molecular Landscape of Lung Adenocarcinoma Published

Collaborative research conducted by scientists within the Cancer Genome Atlas Research Network have identified significant mutations that can influence tumor subtype classification.
Published Online: July 10, 2014
Abstract: Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.

Link to the paper: http://bit.ly/1oFV9OP

Source: Nature

Feature
Recommended Articles
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.
Genevieve Kumapley, PharmD, BCOP, discusses the importance of introducing palliative care to patients at the time of diagnosis and explains how a multidisciplinary team approach can affect the utilization of healthcare resources.
During this Insights interview with Genevieve Kumapley, PharmD, BCOP, on the Use of Oral Oncolytics in Palliative Care, part of the Oncology Stakeholders Summit, Spring 2015 series, Dr Kumapley discusses current guidelines for the delivery of palliative care and describes gaps in care.